Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether he has had discussions with the National Institute for Health and Care Excellence on the prescription of Fampridine as a treatment for MS.

Ministers and departmental officials have regular discussions with the National Institute for Health and Care Excellence (NICE) on a range of issues, including in relation to its guidelines.

NICE’s guideline on the diagnosis and management of multiple sclerosis in adults, published in June 2022, recommends that fampridine should not be offered to treat mobility issues in people with multiple sclerosis as it is not found to be a cost-effective treatment.